IND application submitted to FDA for ALA-101 allogeneic CAR-iNKT cell therapy targeting CD19-positive NHL and leukemias January 4, 2026
Enrollment progress update provided on Ph 3 TERZO study of COPIKTRA (duvelisib) in adults with R/R nodal TFHL December 30, 2025
Japan’s MHLW approves Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with 2L+ FL December 30, 2025
NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for CTCL December 22, 2025
FDA Grants Priority Review to supplemental BLA for Opdivo® + Chemo Combo for Classical Hodgkin Lymphoma December 15, 2025
IND Clearance and EMA Approval of CTA for Ph 1/2 QUADvance Study of AVC-203 for R/R B-cell malignancies announced December 9, 2025
ORR increases to 82% with additional Partial Response in azer-cel CAR T Relapsed Ph 1b trial December 2, 2025
European Commission (EC) grants approval to Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with R/R, BTK inhibitor-treated MCL December 2, 2025
FDA approves EPKINLY® (epcoritamab-bysp), Rituximab and Lenalidomide combo for the Treatment of R/R Follicular Lymphoma November 24, 2025
Positive Data from ANTLER Ph 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010) Announced November 10, 2025
Citius Oncology Signs US Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch November 4, 2025
FDA Fast Track designation for OncoMimics™ immunotherapy EO2463 in follicular lymphoma October 21, 2025
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ October 21, 2025
First patient with follicular lymphoma (FL) dosed in CELESTIAL-301 Ph 1 trial of SynKIR™-310 October 4, 2025
